RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling
Abstract
Authors
L. Cagnan A. Hakmé N. Bénard L. Bensimon J. Alexandre